Effect on survival of estrogen replacement therapy after coronary artery bypass grafting

American Journal of Cardiology

Volumn 79, Issue 7, 1997, Pages 847-850

  Sullivan, Jay M ^a,b   El Zeky, Faten ^a,b   Zwaag, Roger Vander ^a,b   Ramanathan, K B ^a,b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b Div Hlth Serv Res Baptist M   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY OBSTRUCTION; ESTROGEN THERAPY; FEMALE; HEART EJECTION FRACTION; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SURVIVAL;

CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; CORONARY DISEASE; ESTROGEN REPLACEMENT THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIFE TABLES; MIDDLE AGED; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 0030915679     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00001-5     Document Type: Article

References (29)

1. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 20:1991;47-63.
2. Sullivan JM, Vander Zwaag R, Lemp GF, Hughes JP, Maddock V, Kroetz FW, Ramanathan KB, Mirvis DM. Postmenopausal estrogen use and coronary atherosclerosis. Ann Intern Med. 108:1988;358-363.
3. Gruchow HW, Anderson AJ, Barboriak JJ, Sobocinski KA. Postmenopausal use of estrogen and occlusion of coronary arteries. Am Heart J. 115:1988;954-963.
4. McFarland KF, Boniface ME, Hornung CA, Earnhardt W, Humphries JO. Risk factors and noncontraceptive estrogen use in women with and without coronary disease. Am Heart J. 117:1989;1209-1214.
5. Hong MK, Romm PA, Reagan K, Green CE, Rackley CE. Effects of estrogen replacement therapy on serum lipid values and angiographically defined coronary artery disease in postmenopausal women. Am J Cardiol. 69:1992;176-178.
6. Sullivan JM, Vander Zwaag R, Hughes JP, Maddock V, Kroetz FW, Ramanathan KB, Mirvis DM. Estrogen replacement and coronary artery disease-effect on survival in postmenopausal women. Arch Intern Med. 150:1990;2557-2562.
7. Wegner NK, Speroff L, Packard R. Cardiovascular health and disease in women. N Engl J Med. 329:1993;247-256.
8. Loop FD, Golding LR, MacMillan JP, Cosgrove DM, Lytle BW, Sheldon WC. Coronary artery surgery in women compared with men: analyses of risks and long-term results. J Am Coll Cardiol. 1:1983;383-390.
9. Davis KB, Chaitman B, Ryan T, Bittner V, Kennedy JW. Comparison of 15-year survival for men and women after initial medical or surgical treatment for coronary artery disease: a CASS Registry Study. J Am Coll Cardiol. 25:1995;1000-1009.
10. Abbott RD, Wilson PWF, Kannel WB, Castelli WP. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction: The Framingham Study. Arteriosclerosis. 8:1988;207-211.
11. Kannel WB. Metabolic risk factors for coronary heart disease in women: Perspective from the Framingham Study. Am Heart J. 114:1987;413-419.
12. Ettinger B. Hormone replacement therapy and coronary heart disease. Obstet Gynecol Clin North Am. 4:1990;741-757.
13. Rhoads GG, Dahlen G, Berg K, Morton NE, Dannenberg AL. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA. 256:1986;2540-2544.
14. Soma M, Fumagalli R, Paoletti R, Meschia M, Maini MC, Crosignani P, Ghanem K, Gaubatz J, Morrisett JD. Plasma Lp(a) concentration after oestrogen and progestogen in postmenopausal women [letter]. Lancet. 337:1991;612.
15. Furchgott RF, Zawadzk JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 288:1980;373-376.
16. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med. 315:1986;1046-1051.
17. Williams JK, Adams MR, Klopfenstein HS. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation. 81:1990;1680-1687.
18. Herrington DM, Braden GA, Williams JK, Morgan TM. Endothelial-dependent coronary vasomotor responsiveness in postmenopausal women with and without estrogen replacement therapy. Am J of Cardiol. 73:1994;951-952.
19. Reis SE, Gloth ST, Blumenthal RS, Resar JR, Zacur HA, Gerstenblith G, Brinker JA. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation. 89:1994;52-60.
20. Gilligan DM, Quyyumi AA, Cannon RO III. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation. 89:1994;2545-2551.
21. Fogelberg M, Vesterquist O, Diczfalusy U, Henriksson P. Experimental atherosclerosis: effects of estrogen and atherosclerosis on thromboxane and prostacyclin formation. Eur J Clin Invest. 20:1990;105-110.
22. Yui Y, Aoyama T, Morishita H, Takahashi M, Takatsu Y, Kawai C. Serum prostacyclin stabilizing factor is identical to apolipoprotein A-1 (Apo A-1): a novel function of Apo A-1. J Clin Invest. 82:1988;803-807.
23. Collins P, Rosano GMC, Jiang C, Lindsay D, Sarrel PN, Poole-Wilson PA. Cardiovascular protection by oestrogen- a calcium agonist effect. Lancet. 341:1993;1264-1265.
24. Lutola H. Blood pressure and hemodynamics in postmenopausal women during estradiol 17-B substitution. Ann Clin Res. 15:((suppl 38)):1983;119-121.
25. Barret-Connor E, Laakso M. Ischemic heart disease risk in postmenopausal women: effects of estrogen use on glucose and insulin levels. Arteriosclerosis. 10:1990;531-534.
26. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 273:1995;199-208.
27. Gilabert J, Estelles A, Cano A, Espana F, Barrachina R, Grancha S, Aznar J, Tortajada M. The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in postmenopausal status. Am J Obstet Gynecol. 173:1995;1849-1854.
28. Shahar E, Folsom AR, Salomaa VV, Stinson VL, McGovern PG, Shimakawa T, Chambless LE, Wu KK. Relation of hormone-replacement therapy to measures of plasma fibrinolytic activity. Circulation. 93:1996;1970-1975.
29. Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol. 54:1979;74-79.